Solventum (NYSE:SOLV) today announced that it will acquire Acera Surgical in a deal worth up to $900 million.
The deal features a $725 million cash payment, plus up to $125 million in contingent cash payments based on future milestones.
Acera Surgical develops innovative synthetic treatment options for soft tissue repair. It leverages a proprietary electrospinning technology platform. The company’s Restrata products, currently available in the U.S., treat hard-to-heal, complex wounds in acute care settings.
Solventum said that Acera’s innovation engine and commercial footprint align with its leadership in advanced wound care. It expects the company’s relationships and go-to-market capabilities to accelerate adoption of Restrata products in the acute care market and generate synergies by leveraging the global footprint of Solventum, the 3M Health Care spinoff.
The company expects to utilize its specialized wound care sales force and leadership in negative pressure wound therapy to support Restrata.
Solventum expects Acera to generate approximately $90 million in sales in 2025. It anticipates a slightly dilutive impact on adjusted earnings per share (EPS) in 2026, then an accretive one in 2027. The company plans to use cash on hand to finance the deal, which it expects to close in the first half of 2026.
Commentary from Solventum’s CEO on the planned acquisition
Bryan Hanson, Solventum CEO, said:
“Regenerative wound care is an exciting and fast-growing space, and Acera has innovative technology to meet a significant unmet need in acute wound care. Expanding our advanced wound care portfolio into the high-growth synthetic tissue matrices category complements solutions within our existing portfolio and enhances the options our specialized commercial team can provide doctors, nurses, and decision makers within acute care settings.
“This is another bold step in our three-phased transformation plan. Our strong financial performance and the strength of our balance sheet have enabled us to move quickly with our first tuck-in acquisition and the announcement of our first share repurchase program. With Solventum’s broad market presence, depth of clinical partnerships and commitment to advancing healthcare, we are confident this acquisition will create significant value for patients, clinicians and shareholders.”
Share repurchase program initiated
In addition to the acquisition, Solventum announced a share repurchase program, approved by its board of directors.
The program authorizes the company to purchase up to $1 billion of the its outstanding common stock. It expects to begin repurchasing shares next year. The company had approximately 173.4 million shares outstanding as of Oct. 31, 2025.
“Our strong financial performance, operating cash generation, and healthy balance sheet give us the flexibility to invest in opportunities that accelerate sustainable growth, pursue targeted tuck-in M&A—such as today’s announced acquisition of Acera Medical to expand our advanced wound care portfolio—and return capital to shareholders,” said Hanson. “Leveraging this momentum, we are pleased to announce Solventum’s first share repurchase program, an important step in achieving a more balanced capital allocation strategy.”
The analysts’ take
BTIG analysts Ryan Zimmerman and Iseult McMahon maintain a “Neutral” rating for Solventum following the news.
The analysts say they weren’t surprised by the deal, given Solventum’s focus in wound management. However, they note the importance of distinguishing that Acera focuses on higher acuity wounds. The company operates primarily in the inpatient setting, targeting traumatic injuries, complex hernias, plastic reconstructive surgery and more.
Zimmerman and McMahon also note that the deal could prove negative for Integra LifeSciences, which primarily competes in the inpatient segment.
“We like this transaction for [Solventum],” the analysts wrote. “We think it keeps [Solventum’s] focus on the inpatient setting, complementing their existing portfolio in synthetic grafts and providing a high-growth contributor to the portfolio, driving top-line growth in FY26 and beyond.”
